JCR Pharmaceuticals Co (TSE:4552) LT-Debt-to-Total-Asset : 0.13 (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is JCR Pharmaceuticals Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. JCR Pharmaceuticals Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.13.

JCR Pharmaceuticals Co's long-term debt to total assets ratio increased from Dec. 2022 (0.05) to Dec. 2023 (0.13). It may suggest that JCR Pharmaceuticals Co is progressively becoming more dependent on debt to grow their business.

JCR Pharmaceuticals Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for JCR Pharmaceuticals Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JCR Pharmaceuticals Co LT-Debt-to-Total-Asset Chart

JCR Pharmaceuticals Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.08

0.07

0.03

0.06

JCR Pharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.06	0.13	0.13	0.13	-

JCR Pharmaceuticals Co LT-Debt-to-Total-Asset Calculation

JCR Pharmaceuticals Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (A: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2024 )	/	Total Assets (A: Mar. 2024 )
	=	0	/	94937
	=	0.00

JCR Pharmaceuticals Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	13600	/	102773
	=	0.13

JCR Pharmaceuticals Co (TSE:4552) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

JCR Pharmaceuticals Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of JCR Pharmaceuticals Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

JCR Pharmaceuticals Co (TSE:4552) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JCR Pharmaceuticals Co Ltd (TSE:4552) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

JCRRF:USA

Address

3-19 Kasuga-cho, Ashiya, Hyogo, JPN, 659-0021

Website

http://www.jcrpharm.co.jp

JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.

JCR Pharmaceuticals Co (TSE:4552) Headlines

No Headlines